HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

What A Difference A Quarter Can Make: Estee Lauder Companies’ Q3 Results

Executive Summary

From record organic growth to a 9% decline, The Estee Lauder Companies’ fiscal performance over the past two quarters illustrates sharply the devastating and largely unanticipated impact of the COVID-19 pandemic, even for firms best-positioned to ride it out.

You may also be interested in...



Estee Lauder Eliminating Up To 2,000 Heads As It Rationalizes Brick-And-Mortar, Reinvests Online

Lauder’s online business grew at a near triple-digit organic rate in the fiscal 2020 fourth quarter, and the firm intends to go on investing resources accordingly. The firm’s fiscal 2020 net sales slipped 4% to roughly $14.3bn, reported, due to COVID-19 effects.

For Estee Lauder Companies, COVID-19 Has Changed Everything And Nothing

Lauder’s business has been thrashed by COVID-19, but the firm is encouraged that its biggest growth drivers before the crisis are the same ones carrying it through.

L’Oreal Optimistic About Post-Shutdown Growth, Notes Likely Thinning Of Beauty Field

“It's unfortunate, but it's the Darwinian side of this industry,” L’Oreal CEO Jean-Paul Agon said on 16 April while discussing newer players’ prospects for survival through the COVID-19 crisis and L’Oreal’s own first-quarter results – down 4.8% like-for-like, but ahead of the market.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149993

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel